Gujarat Inject Kerala Sets Revised Record Date for 10:1 Stock Split Amid Explosive Earnings and Solar Pivot

Gujarat Inject (Kerala) Limited (GIKL) has officially revised the record date for its upcoming 10:1 equity share sub-division to Wednesday, July 8, 2026. The corporate adjustment, which shifts the deadline from the originally planned July 2 date, coincides with a blockbuster financial performance for the fiscal year ended March 2026 and a rapid operational transformation into the clean energy infrastructure supply chain.

Mechanics of the 10:1 Stock Split

The structural adjustment is aimed at driving market liquidity and broadening retail investor participation. The sub-division mechanics will function as follows:

- The Split Ratio: Ten new equity shares will be issued for every one existing equity share held by investors.

- Affordability and Liquidity: By breaking down the individual stock price proportionally, the split lowers financial barriers to entry, enabling smaller retail participants to trade the asset with tighter bid-ask spreads and minimal price slippage.

- Eligibility Window: Investors whose names are logged in the company's registers or depository accounts as beneficial owners by the close of business hours on Wednesday, July 8, 2026, will be entitled to receive the sub-divided shares.

Blockbuster Financial Highlights (FY 2025-26)

The upcoming stock split is backed by an explosive surge in operational profitability and revenue generation, marked by zero debt liabilities and entirely unpledged promoter equity:

Quarterly Revenue Surge: For the quarter ended March 31, 2026, net sales jumped an incredible 624.06% YoY to hit ₹30.70 crore, climbing rapidly from the ₹4.24 crore recorded in the corresponding March 2025 quarter.

Quarterly Profit After Tax (PAT): Net profit for the March 2026 quarter skyrocketed by 2,242.86% YoY to land at ₹1.64 crore, compared to a razor-thin ₹0.07 crore base in the previous fiscal year's final quarter.

Full-Year Growth: For the full fiscal year ended March 2026, cumulative revenues advanced 90.66% to ₹36.32 crore (up from ₹19.05 crore in FY25), while full-year PAT increased 77.45% to reach ₹1.81 crore (up from ₹1.02 crore in FY25).

Renewable Clean Energy Pivot and Order Wins

To mirror its operational migration into India's booming solar value chain, the company is executing a strategic corporate rebranding to Regenova Renewtech Limited. The business shift is supported by recent commercial order wins exceeding ₹11.6 crore:

Deon Energy Limited Mandate: A contract valued at ₹4.49 crore (exclusive of GST) to supply and deliver 16,129 units of high-capacity 620 Wp Solar Photovoltaic (PV) modules.

Ottire Lifestyle Supply Contract: A focused commercial order valued at ₹1.07 crore for 1,334 units of specialized 600 Wp solar PV modules.

Pipeline Scalability: An independent solar module order secured in early June 2026 valued at ₹6.07 crore, cementing the company's delivery pipeline.

"Backed by an extraordinary 2,242% increase in our March quarterly net profit and over ₹11.6 crore in recent solar order wins, we are executing a highly successful pivot into renewable energy," a company spokesperson stated in management commentary.

Shares of Gujarat Inject Kerala Limited was last trading in BSE at Rs. 130.85 as compared to the previous close of Rs. 130.90. The total number of shares traded during the day was 104402 in over 1600 trades.

The stock hit an intraday high of Rs. 137.00 and intraday low of 130.00. The net turnover during the day was Rs. 14019620.00.

Source : Equity Bulls

Keywords

INE659F01014 GujaratInjectKerala Pharmaceuticals StockSplit SubDivision